Protalix Biotherapeutics Inc (PLX) — Cash Flow Quality Index
Protalix Biotherapeutics Inc (PLX) has a Cash Flow Quality Index of 1.85x as of December 2025. Operating cash flow of $2.03 Million exceeds net income of $1.10 Million, indicating high earnings quality where cash backs reported profits. Explore Protalix Biotherapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Protalix Biotherapeutics Inc Cash Flow Quality Index (1996–2024)
Historical Cash Flow Quality Index for Protalix Biotherapeutics Inc across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Protalix Biotherapeutics Inc (PLX) cash flow conversion.
Annual Cash Flow Quality Index for Protalix Biotherapeutics Inc (1996–2024)
Year-by-year earnings quality comparison for Protalix Biotherapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 2.96x | $8.67 Million | $2.93 Million | ▲ +1965.7% |
| 2023 | -0.16x | $-1.32 Million | $8.31 Million | ▲ +92.4% |
| 1997 | -2.09x | $-247.92K | $118.44K | ▼ -579.4% |
| 1996 | -0.31x | $-40.57K | $131.68K | — |